Results 241 to 250 of about 5,663,674 (349)
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source
The Conflict of Interest That is So Grave That We All Prefer to Ignore It?
Yanovskiy K, Socol Y.
europepmc +1 more source
Loss of primary cilia in endothelial cells promotes EndMT and vascular abnormalities in the ovarian tumor microenvironment through EphA2 activation. Using human samples, in vitro models, and endothelial‐specific Kif3a‐knockout mice, we show that primary cilia loss drives the acquisition of cancer‐associated fibroblast‐like phenotypes, thereby ...
Jin Gu Cho+11 more
wiley +1 more source
Conflict of interest in academic research
Dennis R Trune, Todd T Sherer
openalex +2 more sources
Conflict of Interest? What conflict of interest?
openaire +2 more sources
The importance of patients in conflict of interest declarations. [PDF]
Mainous AG, Struelens MJ, Bao S.
europepmc +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski+19 more
wiley +1 more source
Correction: Managing institutional conflicts: Stakeholder accounts of communication between conflict of interest and technology transfer offices. [PDF]
PLOS ONE Staff.
europepmc +1 more source